ChanTest, FDA Partner on Cardiac Safety Assays
June 10, 2011
ChanTest, FDA Partner on Cardiac Safety Assays
ChanTest will develop non-clinical assays, databases, and computational models for assessing the risk of serious cardiac events associated with drug-induced QT prolongation.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- BioFocus to Offer ChanTest Cell Line Library, Services
February 6, 2013 / GenomeWeb Daily News - Agilent to Collaborate with FDA on Food Pathogen Testing
March 19, 2012 / GenomeWeb Daily News - Roche, ChanTest Ink Deal to Evaluate Safety of Compounds
December 5, 2011 / GenomeWeb Daily News - Molecular Devices Inks Deal with ChanTest for Ion Channel, GPCR Cell Lines
March 24, 2011 / GenomeWeb Daily News - AB Sciex API 3200MD and 3200MD QTRAP Mass Specs Receive EU CE-IVDD Mark
May 20, 2013 / ProteoMonitor